Autoantibodies as biomarkers for lipodystrophy
US-2024019431-A1 · Jan 18, 2024 · US
Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity · Cooperative Patent Classification (CPC)
Computing, optics, measurement, and control technologies.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | G01N2800/044 |
| Official title | Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity |
| Display label | Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity |
| Total patents | 216 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is declining.
| Year | Patents |
|---|---|
| 2015 | 23 |
| 2016 | 31 |
| 2017 | 18 |
| 2018 | 29 |
| 2019 | 24 |
| 2020 | 9 |
| 2021 | 17 |
| 2022 | 17 |
| 2023 | 13 |
| 2024 | 20 |
| 2025 | 10 |
| 2026 | 5 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity
US-2017350903-A1 · Dec 7, 2017 · US
Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity
US-9778268-B2 · Oct 3, 2017 · US
Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
US-2017266079-A1 · Sep 21, 2017 · US
Oxygenated cholesterol sulfates for therapy of disorders caused by at least one of attenuated leptin activity and a lipid storage disorder
US-2017252355-A1 · Sep 7, 2017 · US
Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions
US-9754080-B2 · Sep 5, 2017 · US
Indoxyl sulfate as a biomarker of prebiotic efficacy for weight gain prevention
US-9523671-B2 · Dec 20, 2016 · US
Biomarkers of Mineralocorticoid Receptor Activation
US-2016362744-A1 · Dec 15, 2016 · US
Alpha-keto-isovalerate as a biomarker of prebiotic efficacy for weight gain prevention
US-9518975-B2 · Dec 13, 2016 · US
Droplet actuators and techniques for droplet-based enzymatic assays
US-9513253-B2 · Dec 6, 2016 · US
Isovalerylglycine as biomarker for the predispositon for weight gain and obesity
US-9500660-B2 · Nov 22, 2016 · US
Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker
US-2016327548-A1 · Nov 10, 2016 · US
Methods for predicting overweight risk for pets and adult percent body fat
US-2016281142-A1 · Sep 29, 2016 · US
Polymorphism in CYP3A4 gene affecting drug metabolizing and uses thereof
US-9441275-B2 · Sep 13, 2016 · US
Markers for lipid metabolism
US-2016237502-A1 · Aug 18, 2016 · US
Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions
US-2016232280-A1 · Aug 11, 2016 · US
Hexanoylglycine as biomarker for the predisposition for weight gain and obesity
US-9410963-B2 · Aug 9, 2016 · US
Method of lipid assay and reagent for use therein
US-2016209434-A1 · Jul 21, 2016 · US
Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same
US-2016177371-A1 · Jun 23, 2016 · US
Detection of alpha, beta-dicarbonyl compounds with fluorogenic probes
US-2016178637-A1 · Jun 23, 2016 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC G01N2800/044?
- CPC G01N2800/044 is the Cooperative Patent Classification code for “Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity.”
- How many patents are filed under CPC G01N2800/044 (Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity)?
- Our database includes 216 publications tagged with this CPC code.
- Is patent activity under CPC G01N2800/044 growing?
- Publication counts under this code: 20 in 2024 vs 10 in 2025 (latest complete years).